Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Gossamer Bio (GOSS) stocks in Canada

Learn how to easily invest in Gossamer Bio stocks.

Gossamer Bio is a biotechnology business based in the US. Gossamer Bio stocks (GOSS.US) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $7.96 – a decrease of 0.84% over the previous week. Gossamer Bio employs 195 staff and has a market cap (total outstanding stock value) of $913.7 million.

How to buy shares in Gossamer Bio

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – GOSS – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Is it a good time to buy Gossamer Bio stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

How has Coronavirus impacted Gossamer Bio's stock price?

Since the stock market crash in March caused by coronavirus, Gossamer Bio's stock price has had significant negative movement.

Its last market close was $11.85, which is 20.95% down on its pre-crash value of $14.99 and 57.58% up on the lowest point reached during the March crash when the stocks fell as low as $7.52.

If you had bought $1,000 worth of Gossamer Bio stocks at the start of February 2020, those stocks would have been worth $687.65 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth $868.72.

Gossamer Bio stock price (NASDAQ:GOSS)

Use our graph to track the performance of GOSS stocks over time.

Gossamer Bio shares at a glance

Information last updated 2022-01-10.
Latest market close$11.85
52-week range$7.04 - $14.30
50-day moving average $11.46
200-day moving average $9.95
Wall St. target price$19.63
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-3.26

Compare online stock trading platforms

Note: The dollar amounts in the table below are in Canadian dollars.

Name Product Finder Rating Stock Trading Fee Account Fee Available Asset Types Feature Table description
FREE TRADES
Wealthsimple Trade
Finder Rating:
★★★★★
3.9 / 5
$0
$0
Stocks, ETFs
Get 2 free stocks (total value up to $9,000) when you deposit and trade $150.
Pay no commissions when you trade Canadian stocks and ETFs with Wealthsimple Trade.
Scotia iTRADE
Finder Rating:
★★★★★
3.8 / 5
$4.99 - $9.99
$0
Bonds, Options, Mutual Funds, ETFs, GICs, International Equities
Buy, sell and trade ETFs, Equities, Options and more with competitive commissions.
Interactive Brokers
Finder Rating:
★★★★★
4.1 / 5
Min. $1.00, Max. 0.5%
$0
Stocks, Bonds, Options, ETFs, Currencies, Futures
Extensive trading capabilities and global investment tracking.
Access market data 24 hours a day, six days a week and invest in global stocks, options, futures, currencies, bonds and funds from one single account.
OFFER
CIBC Investor's Edge
Finder Rating:
★★★★★
4 / 5
$4.95 - $6.95
$0 if conditions met, otherwise $100/year
Stocks, Bonds, Options, Mutual Funds, ETFs
Get up to $2,000 cash back. Conditions apply. Offer ends March 1, 2022.
An intuitive and easy-to-use platform with access to a variety of tools that help you make smart decisions and trade with confidence.
Questrade
Finder Rating:
★★★★★
4.2 / 5
$4.95 - $9.95
$0
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs, International Equities, Precious Metals
Get $50 in free trades when you fund your account with a minimum of $1,000.
Opt for self-directed investing and save on fees or get a pre-built portfolio and take some of the guesswork out.
Qtrade Direct Investing
Finder Rating:
★★★★★
4.1 / 5
$6.95 - $8.75
$0 if conditions met, otherwise $25/quarter
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs
Get a $50 bonus when you open a new RRSP, TFSA or RESP and start pre-authorized contributions of at least $200/month. Valid until March 1, 2022.
Qtrade Direct Investing offers low trading commissions and an easy-to-use platform with access to powerful tools and a wide selection of investment options. Trade 100 ETFs free of charge and thousands more for $8.75 or lower.
loading

Compare up to 4 providers

Online stock trading

Gossamer Bio price performance over time

Historical closes compared with the close of $11.85 from 2022-01-14

1 week (2022-01-07) -0.84%
1 month (2021-12-16) 17.09%
3 months (2021-10-15) -15.78%
6 months (2021-07-16) 62.11%
1 year (2021-01-15) 15.16%
2 years (2020-01-16) -21.00%
3 years (2019-01-12) N/A
5 years (2017-01-12) N/A

Gossamer Bio financials

Gross profit TTM $0
Return on assets TTM -27.9%
Return on equity TTM -89.43%
Profit margin 0%
Book value $2.35
Market capitalisation $913.7 million

TTM: trailing 12 months

Gossamer Bio share dividends

We're not expecting Gossamer Bio to pay a dividend over the next 12 months.

Gossamer Bio share price volatility

Over the last 12 months, Gossamer Bio's shares have ranged in value from as little as $7.04 up to $14.3. A popular way to gauge a stock's volatility is its "beta".

GOSS.US volatility(beta: 0.98)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Gossamer Bio's is 0.9807. This would suggest that Gossamer Bio's shares are less volatile than average (for this exchange).

Gossamer Bio overview

Gossamer Bio, Inc. , a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. It is developing GB001, an oral antagonist of prostaglandin D2 receptor 2, which is in Phase IIb clinical trial for the treatment of moderate-to-severe eosinophilic asthma; in Phase II clinical trial to treat patients with chronic rhinosinusitis with and without nasal polyps; and in Phase 2 clinical trial in patients with chronic spontaneous urticarial. The company is also developing GB002, an orally inhaled, small molecule, platelet-derived growth factor receptor kinase inhibitor in Phase Ib clinical trial for the treatment of pulmonary arterial hypertension; GB004, a gut-targeted, oral small molecule in Phase Ib clinical trial for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; and GB1275, an oral, small molecule, CD11b modulator in Phase 1/2 clinical trial for the treatment of selected solid tumor types. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds; and Aerpio Pharmaceuticals, Inc. to develop and commercialize GB004 and related compounds.

Stocks similar to Gossamer Bio

Frequently asked questions

Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, CFDs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading CFDs and forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

More on investing

More guides on Finder

Ask an Expert

You must be logged in to post a comment.

Go to site